- Home
- CLCO vs URGN Comparison
CLCO vs URGN Comparison
Compare CLCO & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLCO
- URGN
- Stock Information
- Founded
- CLCO 2018
- URGN 2004
- Country
- CLCO United Kingdom
- URGN United States
- Employees
- CLCO N/A
- URGN N/A
- Industry
- CLCO
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- CLCO
- URGN Health Care
- Exchange
- CLCO Nasdaq
- URGN Nasdaq
- Market Cap
- CLCO 624.0M
- URGN 547.1M
- IPO Year
- CLCO N/A
- URGN 2017
- Fundamental
- Price
- CLCO $11.39
- URGN $12.84
- Analyst Decision
- CLCO
- URGN Strong Buy
- Analyst Count
- CLCO 0
- URGN 5
- Target Price
- CLCO N/A
- URGN $44.50
- AVG Volume (30 Days)
- CLCO 135.7K
- URGN 764.9K
- Earning Date
- CLCO 11-26-2024
- URGN 11-12-2024
- Dividend Yield
- CLCO 14.39%
- URGN N/A
- EPS Growth
- CLCO N/A
- URGN N/A
- EPS
- CLCO 2.30
- URGN N/A
- Revenue
- CLCO $343,523,000.00
- URGN $85,011,000.00
- Revenue This Year
- CLCO N/A
- URGN $16.49
- Revenue Next Year
- CLCO $11.16
- URGN $57.58
- P/E Ratio
- CLCO $4.96
- URGN N/A
- Revenue Growth
- CLCO 1.46
- URGN 17.22
- 52 Week Low
- CLCO $10.07
- URGN $10.60
- 52 Week High
- CLCO $13.94
- URGN $20.70
- Technical
- Relative Strength Index (RSI)
- CLCO 50.45
- URGN 49.60
- Support Level
- CLCO $11.26
- URGN $11.84
- Resistance Level
- CLCO $11.63
- URGN $13.54
- Average True Range (ATR)
- CLCO 0.20
- URGN 0.82
- MACD
- CLCO 0.01
- URGN 0.08
- Stochastic Oscillator
- CLCO 54.93
- URGN 65.88
About CLCO Cool Company Ltd.
Cool Co Ltd is a LNG shipping company. The company is engaged in the acquisition, ownership, operation and chartering of liquefied natural gas (LNG) carriers (LNGCs), and the operation of third party fleets under management agreements.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.